Welcome to our dedicated page for Oaktree Acquisition III SEC filings (Ticker: OACCW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oaktree Acquisition Corp III’s life-sciences mandate makes its SEC filings anything but routine. One 8-K may reveal a game-changing biotech target; the next S-4 spans hundreds of pages on sponsor promote, redemption math, and warrant dilution. Sifting through those documents to spot key timelines or understand how OACCW warrants convert can be daunting.
Stock Titan’s AI solves that problem. We stream every filing straight from EDGAR—Form 8-K for merger announcements, 10-Q once the business combination closes, even the proxy statement on executive compensation—and generate plain-English summaries within seconds. Want to track Oaktree Acquisition Corp III insider trading Form 4 transactions or get a breakdown of trust-account movements? Our algorithms highlight the numbers and flag unusual activity, so you don’t waste hours combing through footnotes.
Use this page to:
- Receive real-time alerts for Oaktree Acquisition Corp III Form 4 insider transactions and warrant exercises
- See the Oaktree Acquisition Corp III quarterly earnings report 10-Q filing—with AI commentary on post-merger cash burn
- Read an Oaktree Acquisition Corp III annual report 10-K simplified for long-term risk factors
- Understand every Oaktree Acquisition Corp III 8-K material events explained, from extension votes to definitive merger agreements
Whether you’re evaluating redemption scenarios, following Oaktree Acquisition Corp III executive stock transactions Form 4, or simply looking for an Oaktree Acquisition Corp III earnings report filing analysis, our platform keeps the complexities of SPAC disclosures manageable. Understanding Oaktree Acquisition Corp III SEC documents with AI—that’s the edge professional investors need.
Amaze Holdings, Inc. (NYSE American: AMZE), formerly Fresh Vine Wine, filed an 8-K dated 11 July 2025 to disclose a new consulting agreement and related unregistered share issuance.
- Consulting Agreement: Signed 11 July 2025 with DNA Holdings Venture Inc. (Puerto Rico) for a 12-month term, auto-renewable for another 12 months unless cancelled on 30-days notice.
- Scope of Services: Crypto strategy & token architecture, e-commerce/Web3 integration, cross-border currency solutions, credibility/visibility support and market-making for the Company’s planned Token Generation Event.
- Consideration: Company issued 100,000 common shares to the Consultant. No cash payment disclosed.
- Unregistered Securities: Shares issued under Section 4(a)(2) and/or Rule 506(b) of Regulation D, relying on the private-offering exemption.
- Reg FD: A press release announcing the agreement was furnished as Exhibit 99.1 on 15 July 2025.
- Exhibits: 10.1 (Consulting Agreement), 99.1 (Press Release), 104 (Cover Page iXBRL file).
No financial performance metrics were provided in this filing. The transaction introduces crypto-related strategic initiatives while creating modest share dilution.
FAQ
What is the current stock price of Oaktree Acquisition III (OACCW)?
What is Oaktree Acquisition Corp III Life Sciences?
How does the company generate revenue?
What does the term 'blank check company' mean?
How does Oaktree Acquisition Corp III differentiate itself from other SPACs?
What industries does the company target?
How is due diligence conducted?
What role do industry experts play in the company's operations?
How does this SPAC structure benefit investors?
